OWC Pharmaceutical Research Corp. (OWCP) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
2 BEN GURION ST. RAMAT GAN, 5257334 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 3841 - Surgical and Medical Instruments and Apparatus (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2019 MRQ | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 3,464 | 971 | 472 | 357 | 1,469 | 2 | |||
| Cash and cash equivalents | 3,464 | 971 | 472 | 357 | 1,469 | 2 | |||
| Other current assets | 52 | 74 | 9 | ||||||
| Other undisclosed current assets | 50 | 24 | |||||||
| Total current assets: | 3,516 | 1,045 | 482 | 408 | 1,493 | 2 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 37 | 16 | 15 | 23 | 29 | ||||
| Total noncurrent assets: | 37 | 16 | 15 | 23 | 29 | ||||
| TOTAL ASSETS: | 3,553 | 1,061 | 497 | 430 | 1,523 | 2 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 98 | 65 | 8 | 25 | 17 | ||||
| Accounts payable | 98 | 65 | 8 | 17 | |||||
| Accrued liabilities | 25 | ||||||||
| Debt | 3 | ||||||||
| Estimated litigation liability | 15 | ||||||||
| Other liabilities | 240 | 106 | 38 | ||||||
| Deferred revenue and credits | ✕ | ✕ | 100 | 100 | |||||
| Customer advances and deposits | ✕ | ✕ | 50 | ✕ | |||||
| Other undisclosed current liabilities | 85 | 30 | 44 | 128 | |||||
| Total current liabilities: | 438 | 270 | 146 | 108 | 60 | 128 | |||
| Noncurrent Liabilities | |||||||||
| Other undisclosed noncurrent liabilities | 10,329 | 250 | |||||||
| Total noncurrent liabilities: | 10,329 | 250 | |||||||
| Total liabilities: | 10,767 | 270 | 396 | 108 | 60 | 128 | |||
| Temporary equity, carrying amount | 2,226 | ||||||||
| Equity | |||||||||
| Equity, attributable to parent, including: | (9,440) | 791 | 101 | 323 | 1,463 | 697 | |||
| Common stock | 2 | 1 | 1 | 1 | 1 | 0 | |||
| Common stock, share subscribed but unissued, subscriptions receivable | (239) | (344) | (652) | 652 | |||||
| Additional paid in capital | 18,137 | 16,168 | 11,037 | 8,534 | 8,001 | 697 | |||
| Accumulated other comprehensive income (loss) | 3 | 6 | 6 | (11) | |||||
| Accumulated deficit | (27,222) | (14,517) | (9,836) | (7,549) | (5,894) | ||||
| Other undisclosed equity, attributable to parent | (121) | (525) | (455) | (1,303) | (645) | ||||
| Other undisclosed equity | (823) | ||||||||
| Total equity: | (9,440) | 791 | 101 | 323 | 1,463 | (126) | |||
| TOTAL LIABILITIES AND EQUITY: | 3,553 | 1,061 | 497 | 430 | 1,523 | 2 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 50 | |||||||
| Cost of revenue (Financial Services Costs) | (5) | (189) | ||||||
| Gross profit: | (5) | (139) | ||||||
| Operating expenses | (4,296) | 4,554 | 2,148 | (1,651) | (5,034) | (231) | ||
| Other undisclosed operating loss | (9,103) | (4,107) | ||||||
| Operating loss: | (4,296) | (4,554) | (2,098) | (1,651) | (5,034) | (231) | ||
| Nonoperating income | 3 | 0 | ||||||
| Investment income, nonoperating | 0 | |||||||
| Other nonoperating income | 3 | |||||||
| Interest and debt expense | 0 | 3 | 16 | |||||
| Loss from continuing operations: | (4,293) | (4,554) | (2,098) | (1,651) | (5,030) | (215) | ||
| Loss before gain (loss) on sale of properties: | (4,293) | (4,554) | (2,098) | (1,651) | (5,030) | (215) | ||
| Net loss: | (4,293) | (4,554) | (2,098) | (1,651) | (5,030) | (215) | ||
| Other undisclosed net loss attributable to parent | (5,965) | (5) | (189) | (4) | (40) | (103) | ||
| Net loss attributable to parent: | (10,258) | (4,558) | (2,287) | (1,655) | (5,071) | (318) | ||
| Preferred stock dividends and other adjustments | (2,447) | |||||||
| Net loss available to common stockholders, diluted: | (12,705) | (4,558) | (2,287) | (1,655) | (5,071) | (318) | ||
Comprehensive Income ($ in thousands)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (4,293) | (4,554) | (2,098) | (1,651) | (5,030) | (215) | ||
| Other comprehensive income (loss) | (3) | 0 | 2,270 | (1,672) | ||||
| Other undisclosed comprehensive income | 14,557 | |||||||
| Comprehensive income (loss), net of tax, attributable to parent: | 10,261 | (4,553) | 172 | (3,323) | (5,030) | (215) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.